When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Profilaxia pós-exposição ao vírus da imunodeficiência humana (HIV)

Last reviewed: 20 Aug 2025
Last updated: 01 Aug 2023

Summary

Definition

History and exam

Key diagnostic factors

  • presença de fatores de risco
  • exposição ao vírus da imunodeficiência humana (HIV) nas últimas 72 horas
  • rompimento, deslocamento ou não uso do preservativo
  • história de ejaculação do indivíduo-fonte
  • trauma ou lesão na pele
  • úlceras genitais
  • indivíduo-fonte do grupo de alto risco para viremia do HIV
  • indivíduo-fonte de área geográfica com alta prevalência de infecção pelo HIV
  • história sexual de alto risco na pessoa exposta
  • carga viral do HIV detectável no indivíduo-fonte
Full details

Other diagnostic factors

  • história de exame HIV-negativo no indivíduo-fonte
  • indivíduo-fonte com coinfecção por hepatite
  • resistência antiviral para HIV no indivíduo-fonte
  • medicamentos com prescrição médica atual ou sem prescrição
  • história de alergias a medicamentos
  • doença semelhante à gripe
Full details

Risk factors

  • transfusão de sangue de um doador HIV-positivo
  • compartilhamento de dispositivos para injeção
  • lesão por picada de agulha
  • penetração anal receptiva
  • penetração vaginal receptiva
  • exposição da membrana mucosa
  • penetração anal insertiva
  • penetração vaginal insertiva
  • sexo oral receptivo (felação)
Full details

Diagnostic investigations

1st investigations to order

  • teste de antígeno/anticorpo anti-HIV no sangue (ensaio de imunoadsorção enzimática [ELISA] ou ensaio imunoenzimático [EIE] no sangue)
  • teste laboratorial remoto rápido de HIV
  • testes de função renal
  • testes da função hepática
  • sorologia para hepatite B
  • anticorpo contra o vírus da hepatite C
  • sorologia para sífilis
  • teste de gravidez
  • rastreamento de outras ISTs
Full details

Investigations to consider

  • carga viral do HIV se houver sintomas de soroconversão do HIV
Full details

Treatment algorithm

ACUTE

adultas ou adolescentes ≥13 anos: não gestantes

gestantes ou lactantes

crianças

Contributors

Authors

Ming Jie Lee, BSc(Hons), MBBS, MRCP

Clinical Research Fellow

Department of Infectious Disease

Imperial College London

London

UK

Disclosures

MJL has received consulting fees from Thriva Ltd. and conference reimbursement from Gilead Sciences, Inc., and travel grants from ViiV Healthcare, not related to this work.

Julie Fox, BSc(Hons), MBChB, MRCP, MD

HIV consultant and Honorary Senior Lecturer KCL

Department of HIV

Harrison Wing

Guy’s and St Thomas Hospital NHS Foundation Trust

London

UK

Disclosures

JF declares that she has no competing interests.

Acknowledgements

Dr Ming Jie Lee and Dr Julie Fox would like to gratefully acknowledge Dr Jennifer A. Johnson, Dr Paul Sax, Dr Rebecca Plank, Dr Michael Brady, Dr Emily Cheserem, and Dr Claire M. Naftalin, the previous contributors to this topic.

Disclosures

JAJ declares that she has no competing interests. PS serves as a consultant for Abbott, BMS, Gilead, GSK, Merck, and Janssen. He receives grant support from BMS, Gilead, and GSK. EC has been sponsored by GlaxoSmithKline for several conferences and sponsored by Gilead Sciences, Bristol-Myers Squibb Pharmaceuticals, and Abbott Laboratories to attend various educational programs. CMN has been sponsored by Bristol-Myers Squibb Pharmaceuticals to attend an educational program. CMN is an author of a reference cited in this topic. MB not disclosed. RP declares that she has no competing interests.

Peer reviewers

Professor Margaret Johnson, MB BS, MD, FRCP

Clinical Director

HIV/AIDS Services

Royal Free Hampstead NHS Trust

London

UK

Disclosures

MJ declares that she has no competing interests.

William Rodriguez, MD

Chief Medical Officer

Foundation for Innovative New Diagnostics (FIND)

Campus Biotech

Geneva

Switzerland

Disclosures

Not disclosed.

Peer reviewer acknowledgements

BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.

Disclosures

Peer reviewer affiliations and disclosures pertain to the time of the review.

References

Our in-house evidence and editorial teams collaborate with international expert contributors and peer reviewers to ensure that we provide access to the most clinically relevant information possible.

Key articles

British Association for Sexual Health and HIV; Asanati K, Bhagani S, Boffito M, et al. UK guideline for the use of HIV post-exposure prophylaxis. 2021 [internet publication].Full text

Centers for Disease Control and Prevention; US Department of Health and Human Services. Updated guidelines for antiretroviral postexposure prophylaxis after sexual, injection drug use, or other nonoccupational exposure to HIV - United States, 2016. May 2018 [internet publication].Full text

World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach, 2nd ed. 2016 [internet publication].Full text

New York State Department of Health AIDS Institute. PEP to prevent HIV infection. Aug 2023 [internet publication].Full text

World Health Organization. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV. Jan 2018 [internet publication].Full text

Reference articles

A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.

Use of this content is subject to our disclaimer